https://www.pharmaradar360.com/article/fda-grants-tentative-approval-to-generic-olaparib-tablets-7f31cdcc658daebaPharma Surgeen2026-07-20T16:04:36.000ZFDA Grants Tentative Approval to Generic Olaparib Tabletshttps://www.pharmaradar360.com/article/biotech-startup-breeds-blight-tolerant-american-chestnut-without-any-genetic-def-43b669205f75bf68Pharma Surgeen2026-07-20T15:30:26.000ZBiotech Startup Breeds Blight Tolerant American Chestnut Without Any Genetic Defectshttps://www.pharmaradar360.com/article/everything-to-know-about-bms-nvidia-s-ai-supercomputer-d321ba31ad134563Pharma Surgeen2026-07-20T15:18:55.000ZEverything to know about BMS & NVidia’s AI Supercomputerhttps://www.pharmaradar360.com/article/understanding-agentic-ai-in-clinical-development-ad4c832a0ca862a8Pharma Surgeen2026-07-20T15:17:11.000ZUnderstanding Agentic AI in Clinical Developmenthttps://www.pharmaradar360.com/article/for-global-pharma-exposure-is-the-vaneck-pharmaceutical-etf-or-ishares-healthcar-4eeb6cf50c537ba9Pharma Surgeen2026-07-20T15:16:01.000ZFor Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026?https://www.pharmaradar360.com/article/veraxa-biotech-receives-positive-scientific-advice-from-germany-s-pei-for-its-bi-59c388c9144045ddPharma Surgeen2026-07-20T15:15:28.000ZVERAXA Biotech Receives Positive Scientific Advice from Germany's PEI for its BiTAC®-TCE Programhttps://www.pharmaradar360.com/article/why-legend-biotech-stock-fell-10-despite-record-carvykti-sales-b67d91d941f0b2d4Pharma Surgeen2026-07-20T15:11:23.000ZWhy Legend Biotech stock fell 10% despite record Carvykti saleshttps://www.pharmaradar360.com/article/impact-statement-medical-training-prioritisation-bill-52940a2b7baa5c68Pharma Surgeen2026-07-20T15:01:46.000ZImpact statement: Medical Training (Prioritisation) Billhttps://www.pharmaradar360.com/article/fda-clarifies-false-positive-for-cyclospora-in-taylor-farms-lettuce-nationwide-r-c0d51d6dff7fc2aaPharma Surgeen2026-07-20T15:00:07.000ZFDA clarifies false positive for Cyclospora in Taylor Farms lettuce; nationwide recall in effect.https://www.pharmaradar360.com/article/new-trial-tests-antibody-therapy-to-prevent-blood-cancer-infections-b3d0857b99a533f9Pharma Surgeen2026-07-20T14:57:02.000ZNew trial tests antibody therapy to prevent blood cancer infectionshttps://www.pharmaradar360.com/article/us-naproxen-prices-expected-to-remain-firm-amid-resilient-pharmaceutical-demand-149b540481319a1aPharma Surgeen2026-07-20T14:48:16.000ZUS Naproxen Prices Expected to Remain Firm Amid Resilient Pharmaceutical Demandhttps://www.pharmaradar360.com/article/biovica-comments-on-ninth-order-from-leading-pharmaceutical-customer-4e3248a6ff87e057Pharma Surgeen2026-07-20T14:44:00.000ZBiovica comments on ninth order from leading pharmaceutical customerhttps://www.pharmaradar360.com/article/q-a-psychedelics-cannabis-glp-1s-and-drug-policy-changes-e5e9c55d348fc56bPharma Surgeen2026-07-20T14:40:04.000ZQ&A: Psychedelics, cannabis, GLP-1s and drug policy changeshttps://www.pharmaradar360.com/article/apha-urges-fda-to-put-patient-safety-first-in-review-of-peptide-substances-eac165a9861e829ePharma Surgeen2026-07-20T14:33:07.000ZAPhA urges FDA to put patient safety first in review of peptide substanceshttps://www.pharmaradar360.com/article/judge-tosses-vanda-s-fight-against-fda-s-drug-approval-structure-232d63b01cb4166bPharma Surgeen2026-07-20T14:29:00.000ZJudge Tosses Vanda’s Fight Against FDA’s Drug Approval Structurehttps://www.pharmaradar360.com/article/resmed-ventilator-safety-issue-linked-to-5-serious-injuries-c25897b4c92ab7a6Pharma Surgeen2026-07-20T14:27:55.000ZResmed ventilator safety issue linked to 5 serious injurieshttps://www.pharmaradar360.com/article/practical-guidance-for-pharmaceutical-method-of-use-patent-claims-after-teva-v-e-75360f0d77314446Pharma Surgeen2026-07-20T14:09:50.000ZPractical Guidance for Pharmaceutical Method-of-Use Patent Claims After Teva v. Eli Lilly and In re Xencorhttps://www.pharmaradar360.com/article/fda-s-adequate-provision-rule-proposal-could-accelerate-pharma-s-transition-away-9515f973c8ce6b42Pharma Surgeen2026-07-20T14:07:14.000ZFDA’s adequate provision rule proposal could accelerate pharma’s transition away from TVhttps://www.pharmaradar360.com/article/medicine-supply-disruption-statistics-uk-data-to-june-2026-5ce9d540fae1527cPharma Surgeen2026-07-20T14:02:38.000ZMedicine supply disruption statistics, UK: data to June 2026https://www.pharmaradar360.com/article/dianthus-therapeutics-stock-surges-after-initiating-major-phase-3-clinical-trial-340144e14490304bPharma Surgeen2026-07-20T14:01:44.000ZDianthus Therapeutics Stock Surges After Initiating Major Phase 3 Clinical Trialhttps://www.pharmaradar360.com/article/tempus-buys-out-cancer-genomics-specialist-personalis-in-1-5-billion-deal-3fb06c03408e3128Pharma Surgeen2026-07-20T13:55:05.000ZTempus buys out cancer genomics specialist Personalis in $1.5 billion dealhttps://www.pharmaradar360.com/article/scribe-aims-for-96m-ipo-to-fund-lipid-lowering-genetic-meds-ec8b13b5850ce750Pharma Surgeen2026-07-20T13:48:41.000ZScribe aims for $96M IPO to fund lipid-lowering genetic medshttps://www.pharmaradar360.com/article/unfamiliar-odor-caused-large-ems-response-at-grifols-pharmaceutical-plant-in-cla-ae24d2f34adfae05Pharma Surgeen2026-07-20T13:47:43.000ZUnfamiliar odor caused large EMS response at Grifols pharmaceutical plant in Claytonhttps://www.pharmaradar360.com/article/trump-purge-at-fda-and-usda-triggers-food-safety-brain-drain-211ed6056a9146daPharma Surgeen2026-07-20T13:41:02.000ZTrump purge at FDA and USDA triggers food safety ‘brain drain’https://www.pharmaradar360.com/article/a-most-wanted-fugitive-appears-to-have-been-secretly-working-as-a-biotech-execut-152fdf6f6dc8cdf1Pharma Surgeen2026-07-20T13:38:35.000ZA most-wanted fugitive appears to have been secretly working as a biotech executivehttps://www.pharmaradar360.com/article/what-cold-chain-tech-trends-are-reshaping-pharma-logistics-2a4efb2a1bd5d6adPharma Surgeen2026-07-20T13:31:06.000ZWhat Cold Chain Tech Trends Are Reshaping Pharma Logistics?https://www.pharmaradar360.com/article/930-dead-in-outbreak-fda-backtracks-on-iceberg-lettuce-chronic-cough-drug-fizzle-9c1468c539156e90Pharma Surgeen2026-07-20T13:29:41.000Z930 Dead in Outbreak; FDA Backtracks on Iceberg Lettuce; Chronic Cough Drug Fizzleshttps://www.pharmaradar360.com/article/kolon-s-cell-based-gene-therapy-fails-phase-3-osteoarthritis-trial-f5816d360acfc0a4Pharma Surgeen2026-07-20T13:25:12.000ZKolon’s cell-based gene therapy fails phase 3 osteoarthritis trialhttps://www.pharmaradar360.com/article/fda-reverses-positive-cyclospora-lettuce-test-result-as-taylor-farms-recall-stay-1151247cc20fffb3Pharma Surgeen2026-07-20T13:23:39.000ZFDA Reverses Positive Cyclospora Lettuce Test Result as Taylor Farms Recall Stays in Effect Nationwidehttps://www.pharmaradar360.com/article/stephens-adjusts-west-pharmaceutical-services-price-target-to-410-from-360-maint-cb30e1c7d1f6bfb0Pharma Surgeen2026-07-20T13:16:38.000ZStephens Adjusts West Pharmaceutical Services Price Target to $410 From $360, Maintains Overweight Ratinghttps://www.pharmaradar360.com/article/nucana-stock-holds-value-as-cash-runway-and-clinical-pipeline-shape-outlook-5a7705e45c5216dbPharma Surgeen2026-07-20T13:11:24.000ZNuCana stock holds value as cash runway and clinical pipeline shape outlookhttps://www.pharmaradar360.com/article/u-s-food-and-drug-administration-apologizes-to-taylor-farms-for-false-cyclospora-77c722644e2d1611Pharma Surgeen2026-07-20T13:11:16.000ZU.S. Food And Drug Administration Apologizes to Taylor Farms For False Cyclospora Test Resultshttps://www.pharmaradar360.com/article/biotech-pre-market-pulse-advb-camp-swing-big-bivi-drops-f497a49db6107094Pharma Surgeen2026-07-20T13:02:00.000ZBiotech Pre-Market Pulse: ADVB, CAMP Swing Big; BIVI Dropshttps://www.pharmaradar360.com/article/class-4-medicines-defect-notification-macarthys-laboratories-ltd-t-a-martindale-809d10a2945ae639Pharma Surgeen2026-07-20T13:01:18.000ZClass 4 Medicines Defect Notification: Macarthys Laboratories Ltd T/A Martindale Pharma, Xaggitin XL Prolonged-release Tablets, EL(26)A/35https://www.pharmaradar360.com/article/investigational-anal-cancer-therapy-posts-30-response-rate-43289c44e23040cfPharma Surgeen2026-07-20T13:00:00.000ZInvestigational anal cancer therapy posts 30% response ratehttps://www.pharmaradar360.com/article/oncolytics-biotech-receives-fast-track-designation-for-pelareorep-in-second-line-2ac6e590e90d2f0bPharma Surgeen2026-07-20T13:00:00.000ZOncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancerhttps://www.pharmaradar360.com/article/global-health-advances-a-dive-into-breakthroughs-and-challenges-8b522a157aae33b3Pharma Surgeen2026-07-20T12:58:45.000ZGlobal Health Advances: A Dive into Breakthroughs and Challengeshttps://www.pharmaradar360.com/article/samsung-biologics-to-buy-polypeptide-for-1-9-bn-in-korea-s-biggest-pharma-deal-2f55980827888015Pharma Surgeen2026-07-20T12:54:03.000ZSamsung Biologics to buy PolyPeptide for $1.9 bn in Korea’s biggest pharma dealhttps://www.pharmaradar360.com/article/uk-biotech-financing-continues-growth-reaching-five-year-high-922b8a5cc93d2d29Pharma Surgeen2026-07-20T12:41:31.000ZUK biotech financing continues growth, reaching five-year highhttps://www.pharmaradar360.com/article/abpi-comment-on-resignation-of-lord-vallance-71bd2d7ea353e733Pharma Surgeen2026-07-20T12:35:48.000ZABPI comment on resignation of Lord Vallancehttps://www.pharmaradar360.com/article/novo-nordisk-launches-cheaper-ozempic-copy-in-south-africa-fc8c14b4608f56d4Pharma Surgeen2026-07-20T12:34:29.000ZNovo Nordisk launches cheaper Ozempic copy in South Africahttps://www.pharmaradar360.com/article/divcowest-welcomes-collegium-pharmaceutical-to-one-lincoln-acff64ae4718f500Pharma Surgeen2026-07-20T12:33:00.000ZDivcoWest Welcomes Collegium Pharmaceutical to One Lincolnhttps://www.pharmaradar360.com/article/okyo-pharma-files-annual-report-highlights-cash-position-and-phase-3-trial-plans-d802871f8d66526cPharma Surgeen2026-07-20T12:33:00.000ZOKYO Pharma files annual report, highlights cash position and Phase 3 trial planshttps://www.pharmaradar360.com/article/keeping-drugs-free-of-contaminants-pharmaceutical-manufacturers-filter-medicatio-5f0218e11d467ab0Pharma Surgeen2026-07-20T12:32:13.000ZKeeping drugs free of contaminants – pharmaceutical manufacturers filter medications through tiny pores to keep them sterile and safehttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-q2-2026-preview-eps-est-2-08-reports-july-23-212d8ae839048149Pharma Surgeen2026-07-20T12:29:50.000ZWest Pharmaceutical Services (WST) Q2 2026 Preview: EPS Est. $2.08, Reports July 23https://www.pharmaradar360.com/article/keeping-drugs-free-of-contaminants-pharmaceutical-manufacturers-filter-medicatio-92b894698c02c85fPharma Surgeen2026-07-20T12:25:43.000ZKeeping drugs free of contaminants – pharmaceutical manufacturers filter medications through tiny pores to keep them sterile and safehttps://www.pharmaradar360.com/article/nuvation-ceo-david-hung-details-leadership-strategies-and-career-motivations-in-395028fc7e6ecb63Pharma Surgeen2026-07-20T12:24:41.000ZNuvation CEO David Hung Details Leadership Strategies and Career Motivations in Biotechhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-rohto-pharmaceutical-co-ltd-gettex-uc1-c940e1debe6e0e31Pharma Surgeen2026-07-20T12:22:03.000ZEnterprise value to EBIT forward of Rohto Pharmaceutical Co., Ltd. – GETTEX:UC1https://www.pharmaradar360.com/article/kolon-tissuegene-s-knee-osteoarthritis-therapy-fails-phase-3-trial-by-investing-615d2d1195662e88Pharma Surgeen2026-07-20T12:16:20.000ZKolon TissueGene’s knee osteoarthritis therapy fails phase 3 trial By Investing.comhttps://www.pharmaradar360.com/article/us-fusidic-acid-prices-decline-13-31-amid-soft-pharmaceutical-demand-b62787317ec142b2Pharma Surgeen2026-07-20T12:13:20.000ZUS Fusidic Acid Prices Decline 13.31% Amid Soft Pharmaceutical Demandhttps://www.pharmaradar360.com/article/fda-says-positive-cyclospora-test-on-taylor-farms-lettuce-was-an-error-the-multi-d387f09cb789ccf0Pharma Surgeen2026-07-20T12:12:35.000ZFDA says positive cyclospora test on Taylor Farms lettuce was an error. The multistate sickness outbreak continues.https://www.pharmaradar360.com/article/la-aemps-publica-dos-nuevas-infografias-informativas-sobre-reconstruccion-mamari-69da9dfc7caeb7b2Pharma Surgeen2026-07-20T12:11:18.000ZLa AEMPS publica dos nuevas infografías informativas sobre reconstrucción mamaria y mamoplastia de aumentohttps://www.pharmaradar360.com/article/after-more-than-20-years-collegium-plans-boston-headquarters-move-5f2fdfeb009a05a0Pharma Surgeen2026-07-20T12:00:00.000ZAfter More Than 20 Years, Collegium Plans Boston Headquarters Movehttps://www.pharmaradar360.com/article/tinlarebant-retinal-marker-stayed-stable-or-fell-2-placebo-rose-20-ca80ce8899b3c8aaPharma Surgeen2026-07-20T12:00:00.000ZTinlarebant retinal marker stayed stable or fell ~2%; placebo rose 20%https://www.pharmaradar360.com/article/collegium-pharmaceutical-announces-new-corporate-headquarters-at-one-lincoln-in-dd299dd843b77b4dPharma Surgeen2026-07-20T12:00:00.000ZCollegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Bostonhttps://www.pharmaradar360.com/article/pharmablock-convenes-global-industry-leaders-in-zurich-to-advance-green-chemistr-d755f15a426a20aaPharma Surgeen2026-07-20T12:00:00.000ZPharmaBlock Convenes Global Industry Leaders in Zurich to Advance Green Chemistry for Sustainable Pharmaceutical Manufacturinghttps://www.pharmaradar360.com/article/biotech-is-booming-this-year-2-reasons-investors-are-excited-8821a16bd1bc6190Pharma Surgeen2026-07-20T12:00:00.000ZBiotech is booming this year: 2 reasons investors are excitedhttps://www.pharmaradar360.com/article/blacklisting-of-onifam-laboratories-ltd-26d8fdca4443091aPharma Surgeen2026-07-20T11:52:02.000ZBlacklisting of Onifam Laboratories Ltdhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-tian-an-pharmaceutical-co-ltd-otc-tnph-442a0bcc7d8eb779Pharma Surgeen2026-07-20T11:46:23.000ZPrice to earnings forward of Tian'an Pharmaceutical Co., Ltd. – OTC:TNPHhttps://www.pharmaradar360.com/article/geopolitics-chills-british-biotech-ipo-plans-despite-2b-in-q2-vc-funds-6a92c0dedbffb76aPharma Surgeen2026-07-20T11:45:20.000ZGeopolitics ‘chills’ British biotech IPO plans, despite $2B in Q2 VC fundshttps://www.pharmaradar360.com/article/armata-advances-ap-sa02-toward-phase-3-trial-launch-fe4fcafd8269802cPharma Surgeen2026-07-20T11:43:24.000ZArmata Advances AP-SA02 Toward Phase 3 Trial Launchhttps://www.pharmaradar360.com/article/h-c-wainwright-reiterates-buy-on-4d-molecular-stock-on-trial-data-902ae239a376994fPharma Surgeen2026-07-20T11:42:00.000ZH.C. Wainwright reiterates Buy on 4D Molecular stock on trial datahttps://www.pharmaradar360.com/article/okyo-pharma-nasdaq-okyo-highlights-cash-for-neptune-phase-3-f14a2cbeaad82a84Pharma Surgeen2026-07-20T11:41:48.000ZOKYO Pharma (Nasdaq: OKYO) highlights cash for NEPTUNE Phase 3https://www.pharmaradar360.com/article/biohaven-s-bhv-1530-targets-fgfr3-tumors-with-or-without-alterations-6d1c5c095db7f8e6Pharma Surgeen2026-07-20T11:33:42.000ZBiohaven’s BHV-1530 targets FGFR3 tumors with or without alterationshttps://www.pharmaradar360.com/article/applications-open-for-biotech-certified-innovation-path-f9ccfdde11a07db9Pharma Surgeen2026-07-20T11:33:12.000ZApplications open for Biotech Certified Innovation Pathhttps://www.pharmaradar360.com/article/okyo-pharma-files-annual-report-and-provides-positive-corporate-update-on-financ-1de8bc1278ebcd38Pharma Surgeen2026-07-20T11:13:00.000ZOKYO Pharma Files Annual Report and Provides Positive Corporate Update on Financial Strength and Phase 3 Urcosimod Trialhttps://www.pharmaradar360.com/article/veraxa-biotech-ag-receives-scientific-advice-from-germany-s-pei-on-bitac-tce-dev-b559e8e8aae55e87Pharma Surgeen2026-07-20T11:13:00.000ZVERAXA Biotech AG Receives Scientific Advice from Germany’s PEI on BiTAC-TCE Development Programhttps://www.pharmaradar360.com/article/armata-submits-phase-3-protocol-for-antibiotic-resistant-drug-46c6d0076f055e28Pharma Surgeen2026-07-20T11:10:51.000ZArmata submits Phase 3 protocol for antibiotic-resistant drughttps://www.pharmaradar360.com/article/veraxa-biotech-announces-regulatory-progress-with-its-bitac-tce-development-plan-cdf089c02ae6022cPharma Surgeen2026-07-20T11:09:28.000ZVERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Planhttps://www.pharmaradar360.com/article/inmune-bio-completes-commercial-manufacturing-milestone-supporting-planned-globa-a3837261f4158f15Pharma Surgeen2026-07-20T11:09:07.000ZINmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platformhttps://www.pharmaradar360.com/article/okyo-pharma-announces-filing-of-annual-report-with-strengthened-cash-position-an-5883e1b0919bfe02Pharma Surgeen2026-07-20T11:08:50.000ZOKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Planshttps://www.pharmaradar360.com/article/can-fite-positive-phase-2a-pancreatic-cancer-study-data-accepted-for-presentatio-e59947b37ad8f19fPharma Surgeen2026-07-20T11:08:46.000ZCan-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncologyhttps://www.pharmaradar360.com/article/pune-fda-s-ai-complaint-portal-receives-293-food-and-drug-complaints-in-four-day-5a2363ea9552ff0cPharma Surgeen2026-07-20T11:08:31.000ZPune: FDA’s AI Complaint Portal Receives 293 Food And Drug Complaints In Four Dayshttps://www.pharmaradar360.com/article/can-ai-fix-pharma-s-last-mile-delivery-blind-spot-fdb0bde08f11c060Pharma Surgeen2026-07-20T11:08:02.000ZCan AI Fix Pharma's Last-Mile Delivery Blind Spot?https://www.pharmaradar360.com/article/uk-biotech-financing-continues-recovery-trajectory-on-five-year-q2-high-7a56054087108e62Pharma Surgeen2026-07-20T11:06:23.000ZUK biotech financing continues recovery trajectory on five-year Q2 highhttps://www.pharmaradar360.com/article/can-fite-biopharma-nyse-canf-to-present-phase-2a-pancreatic-cancer-data-67ba09d6ce162c17Pharma Surgeen2026-07-20T11:04:55.000ZCan-Fite BioPharma (NYSE: CANF) to present Phase 2a pancreatic cancer datahttps://www.pharmaradar360.com/article/systemic-leap-china-s-drug-innovation-push-yields-bumper-crop-3bf723b5e718771dPharma Surgeen2026-07-20T11:00:08.000Z‘Systemic leap’: China’s drug innovation push yields bumper crophttps://www.pharmaradar360.com/article/medtronic-to-announce-financial-results-for-its-first-quarter-of-fiscal-year-202-cdf53bbd085cc097Pharma Surgeen2026-07-20T11:00:00.000ZMedtronic to announce financial results for its first quarter of fiscal year 2027https://www.pharmaradar360.com/article/pancreatic-cancer-patient-alive-18-months-after-second-line-namodenoson-c89743fdac0a1154Pharma Surgeen2026-07-20T11:00:00.000ZPancreatic cancer patient alive 18+ months after second-line Namodenosonhttps://www.pharmaradar360.com/article/inmune-bio-s-cord-tissue-process-supports-planned-phase-3-trial-4e392a24ea47c05bPharma Surgeen2026-07-20T11:00:00.000ZINmune Bio's Cord-Tissue Process Supports Planned Phase 3 Trialhttps://www.pharmaradar360.com/article/compugen-s-cancer-immunotherapy-update-is-set-for-aug-3-042905cbb332ebb2Pharma Surgeen2026-07-20T11:00:00.000ZCompugen's Cancer Immunotherapy Update Is Set for Aug. 3https://www.pharmaradar360.com/article/veraxa-cancer-candidate-targets-two-markers-while-sparing-others-a7a8c86874aa56ccPharma Surgeen2026-07-20T11:00:00.000ZVERAXA cancer candidate targets two markers while sparing othershttps://www.pharmaradar360.com/article/clinigen-appoints-greg-skalicky-as-chief-executive-officer-3c706b48f07d073cPharma Surgeen2026-07-20T11:00:00.000ZClinigen Appoints Greg Skalicky as Chief Executive Officerhttps://www.pharmaradar360.com/article/armata-pharmaceuticals-achieves-key-progress-across-clinical-regulatory-and-manu-bb21ffc3ed042ba3Pharma Surgeen2026-07-20T11:00:00.000ZArmata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02https://www.pharmaradar360.com/article/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-de34734338def5c4Pharma Surgeen2026-07-20T10:59:00.000ZBristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIAhttps://www.pharmaradar360.com/article/betting-on-biotech-clinical-trials-enter-prediction-markets-ae98a736a8f729adPharma Surgeen2026-07-20T10:55:54.000ZBetting on biotech: Clinical trials enter prediction marketshttps://www.pharmaradar360.com/article/mission-therapeutics-divests-acute-kidney-injury-drug-mtx652-in-292m-dimerix-dea-dfd2eada78fbcfa1Pharma Surgeen2026-07-20T10:54:19.000ZMission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix dealhttps://www.pharmaradar360.com/article/ukhsa-s-chief-scientist-reminds-families-how-to-beat-the-heat-as-schools-break-f-caf7d7411e944bb3Pharma Surgeen2026-07-20T10:53:00.000ZUKHSA's Chief Scientist reminds families how to Beat the Heat as schools break for summerhttps://www.pharmaradar360.com/article/price-to-sales-forward-of-hob-biotech-group-corp-ltd-class-a-sse-688656-f41f620c84b6d1f6Pharma Surgeen2026-07-20T10:49:01.000ZPrice to sales forward of HOB Biotech Group Corp., Ltd. Class A – SSE:688656https://www.pharmaradar360.com/article/sound-shore-management-inc-ct-lowers-position-in-teva-pharmaceutical-industries-f0c7d4246ba399e5Pharma Surgeen2026-07-20T10:31:17.000ZSound Shore Management Inc. CT Lowers Position in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/wcm-investment-management-llc-purchases-26-813-522-shares-of-teva-pharmaceutical-2b9ccadaf2ab22a6Pharma Surgeen2026-07-20T10:27:12.000ZWCM Investment Management LLC Purchases 26,813,522 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/uk-biotech-financing-continues-recovery-trajectory-on-five-year-q2-high-101aabbb24a3bb8ePharma Surgeen2026-07-20T10:25:33.000ZUK biotech financing continues recovery trajectory on five-year Q2 highhttps://www.pharmaradar360.com/article/4dmt-reports-positive-2-year-prism-phase-2b-data-for-4d-150-db50f42d5b3adec3Pharma Surgeen2026-07-20T10:22:21.000Z4DMT Reports Positive 2-Year PRISM Phase 2b Data for 4D-150https://www.pharmaradar360.com/article/xencor-shares-kidney-cancer-trial-results-at-esmo-20041aa2b4ee9769Pharma Surgeen2026-07-20T10:21:52.000ZXencor Shares Kidney Cancer Trial Results at ESMOhttps://www.pharmaradar360.com/article/inflammasome-reports-positive-phase-2-k8-results-d643447a8a619d69Pharma Surgeen2026-07-20T10:21:15.000ZInflammasome Reports Positive Phase 2 K8 Resultshttps://www.pharmaradar360.com/article/eli-lilly-bets-3-8-billion-on-ataibeckley-psychedelics-ea33bc341702ab4bPharma Surgeen2026-07-20T10:18:54.000ZEli Lilly Bets $3.8 Billion on AtaiBeckley Psychedelicshttps://www.pharmaradar360.com/article/the-patient-information-leaflet-is-it-really-working-for-patients-a4bc9d2d423e5951Pharma Surgeen2026-07-20T10:13:57.000ZThe patient information leaflet: is it really working for patients?https://www.pharmaradar360.com/article/biotech-breakthroughs-in-treating-uterine-disorders-e65e91bf9c6dd4fePharma Surgeen2026-07-20T10:13:21.000ZBiotech Breakthroughs in Treating Uterine Disordershttps://www.pharmaradar360.com/article/2025-7-66-4316-2014-270-b978e6a115602a41Pharma Surgeen2026-07-20T10:07:43.000ZΠαροχές εταιρειών προϊόντων αρμοδιότητας ΕΟΦ έτους 2025 δυνάμει της παραγράφου 7 του άρθρου 66 του Ν. 4316/2014 (Α΄ 270)https://www.pharmaradar360.com/article/price-to-book-forward-of-hob-biotech-group-corp-ltd-class-a-sse-688656-e952b31032599dc9Pharma Surgeen2026-07-20T10:06:28.000ZPrice to book forward of HOB Biotech Group Corp., Ltd. Class A – SSE:688656https://www.pharmaradar360.com/article/recce-pharmaceuticals-asx-rce-share-purchase-plan-deadline-extended-what-investo-63de4de46a7de840Pharma Surgeen2026-07-20T10:06:00.000ZRecce Pharmaceuticals (ASX:RCE): Share Purchase Plan Deadline Extended---What Investors Need to Knowhttps://www.pharmaradar360.com/article/dwwd-etf-profile-dividends-returns-han-dwwd-3aff3ac07d8ed8daPharma Surgeen2026-07-20T10:04:20.000ZDWWD ETF Profile: Dividends, Returns (HAN:DWWD)https://www.pharmaradar360.com/article/how-exposed-is-the-u-s-pharmaceutical-supply-chain-to-china-s-updated-export-con-09130df36f23b4ffPharma Surgeen2026-07-20T10:03:11.000ZHow Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?https://www.pharmaradar360.com/article/axios-c-suite-pfizer-ceo-on-biotech-s-china-warning-506de2d800745dacPharma Surgeen2026-07-20T10:01:14.000ZAxios C-Suite: Pfizer CEO on biotech's China warninghttps://www.pharmaradar360.com/article/critical-medicines-on-hold-pakistan-s-regulatory-gridlock-risking-lives-c65bdb84ab224897Pharma Surgeen2026-07-20T09:52:44.000ZCritical Medicines on Hold: Pakistan's Regulatory Gridlock Risking Liveshttps://www.pharmaradar360.com/article/lecanemab-for-ad-shows-sustained-benefit-in-real-world-study-11713568d7bcb3d5Pharma Surgeen2026-07-20T09:48:42.000ZLecanemab for AD Shows Sustained Benefit in Real-World Studyhttps://www.pharmaradar360.com/article/fda-crackdown-tukaram-mundhe-reveals-maharashtra-s-biggest-food-complaint-hotspo-060b25c7d3e8594bPharma Surgeen2026-07-20T09:44:16.000ZFDA Crackdown: Tukaram Mundhe Reveals Maharashtra's Biggest Food Complaint Hotspothttps://www.pharmaradar360.com/article/blossomhill-joins-biotech-ipo-stampede-with-small-molecule-bet-b5b7eaba46ea7cf6Pharma Surgeen2026-07-20T09:39:28.000ZBlossomHill joins biotech IPO stampede with small molecule bethttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-16-august-2026-e87634fb03727675Pharma Surgeen2026-07-20T09:36:46.000ZWeekly all-cause mortality surveillance: week ending 16 August 2026https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-19-july-2026-6ea0cfec207911edPharma Surgeen2026-07-20T09:36:30.000ZWeekly all-cause mortality surveillance: week ending 19 July 2026https://www.pharmaradar360.com/article/a-look-cleanroom-technology-events-2026-2027-75b305a67eecfe2cPharma Surgeen2026-07-20T09:21:04.000ZA look: Cleanroom technology events 2026-2027https://www.pharmaradar360.com/article/uk-biotech-venture-investment-reaches-five-year-high-in-q2-2026-fc067bfa69405ae4Pharma Surgeen2026-07-20T09:17:55.000ZUK biotech venture investment reaches five-year high in Q2 2026https://www.pharmaradar360.com/article/india-approves-first-dengue-vaccine-qdenga-for-people-aged-4-60-years-b8a64a7bc4f48314Pharma Surgeen2026-07-20T09:08:52.000ZIndia approves first dengue vaccine QDENGA for people aged 4-60 yearshttps://www.pharmaradar360.com/article/meningococcal-b-menb-time-limited-vaccination-offer-information-for-healthcare-p-a9d27fb6d5e14baePharma Surgeen2026-07-20T09:03:25.000ZMeningococcal B (MenB) time limited vaccination offer: information for healthcare practitionershttps://www.pharmaradar360.com/article/latigo-bets-its-ipo-on-non-opioid-pain-data-51c683fdd7bb0c07Pharma Surgeen2026-07-20T09:00:00.000ZLatigo bets its IPO on non-opioid pain datahttps://www.pharmaradar360.com/article/galderma-rolls-out-alastin-regenerative-skincare-across-jpac-region-c32c8d792f240212Pharma Surgeen2026-07-20T08:59:22.000ZGalderma rolls out Alastin regenerative skincare across JPAC regionhttps://www.pharmaradar360.com/article/uk-biotech-venture-investment-remains-buoyant-in-q2-ab08ab2a9e53eb08Pharma Surgeen2026-07-20T08:58:52.000ZUK biotech venture investment remains buoyant in Q2https://www.pharmaradar360.com/article/dyslipidemia-which-is-familiar-with-hyperlipidemia-is-considered-a-national-chro-169046cd4b486de6Pharma Surgeen2026-07-20T08:46:13.000ZDyslipidemia, which is familiar with hyperlipidemia, is considered a "national chronic disease" alon..https://www.pharmaradar360.com/article/tukaram-mundhe-maharashtra-fda-s-food-safety-enforcement-drive-bc16db20c832cf82Pharma Surgeen2026-07-20T08:41:58.000ZTukaram Mundhe: Maharashtra FDA's Food Safety Enforcement Drivehttps://www.pharmaradar360.com/article/ubfc-etf-profile-dividends-returns-swb-ubfc-2fcfd46b21ec4f71Pharma Surgeen2026-07-20T08:39:12.000ZUBFC ETF Profile: Dividends, Returns (SWB:UBFC)https://www.pharmaradar360.com/article/kolon-tissuegene-s-tg-c-fails-to-meet-statistical-significance-in-u-s-phase-3-8454a49c2174a7a8Pharma Surgeen2026-07-20T08:35:32.000ZKolon TissueGene's TG-C Fails to Meet Statistical Significance in U.S. Phase 3https://www.pharmaradar360.com/article/flu-vaccines-for-children-and-young-people-for-2026-to-2027-750e454b72aae8f2Pharma Surgeen2026-07-20T08:30:07.000ZFlu vaccines for children and young people for 2026 to 2027https://www.pharmaradar360.com/article/flu-vaccination-letter-template-for-at-risk-patients-and-carers-f8d0a2827f858979Pharma Surgeen2026-07-20T08:30:07.000ZFlu vaccination: letter template for at risk patients and carershttps://www.pharmaradar360.com/article/25-transfers-in-two-decades-meet-ias-officer-tukaram-mundhe-leading-maharashtra-53cf7bce17f0791dPharma Surgeen2026-07-20T08:13:03.000Z25 Transfers in Two Decades: Meet IAS Officer Tukaram Mundhe, Leading Maharashtra’s Food Safety Crackdownhttps://www.pharmaradar360.com/article/lundbeck-takes-important-step-in-global-phase-3-trial-with-epilepsy-treatment-ca-c904c4cac934ad66Pharma Surgeen2026-07-20T08:12:01.000ZLundbeck takes important step in global phase 3 trial with epilepsy treatment candidatehttps://www.pharmaradar360.com/article/register-medical-devices-to-place-on-the-market-3019846827ce19e8Pharma Surgeen2026-07-20T08:06:20.000ZRegister medical devices to place on the markethttps://www.pharmaradar360.com/article/guidance-medical-devices-legal-requirements-for-specific-medical-products-a3bc1151bebfa6a3Pharma Surgeen2026-07-20T08:06:17.000ZGuidance: Medical devices: legal requirements for specific medical productshttps://www.pharmaradar360.com/article/guidance-custom-made-medical-devices-in-great-britain-08caf003423fd6bcPharma Surgeen2026-07-20T08:06:13.000ZGuidance: Custom-made medical devices in Great Britainhttps://www.pharmaradar360.com/article/kolon-tissuegene-misses-efficacy-in-us-phase-3-pursues-fda-talks-chosunbiz-beaa3bd1f4f51130Pharma Surgeen2026-07-20T08:02:00.000ZKolon TissueGene misses efficacy in US phase 3, pursues FDA talks - CHOSUNBIZhttps://www.pharmaradar360.com/article/a-rising-tide-scenario-why-other-big-pharmas-could-follow-lilly-into-psychedelic-d34c3d099447c9faPharma Surgeen2026-07-20T08:00:00.000Z‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelicshttps://www.pharmaradar360.com/article/dekaz-e1d1cbcc98a4434aPharma Surgeen2026-07-20T07:58:26.000ZΑνάκληση της Άδειας Χονδρικής πώλησης φαρμάκων για Ανθρώπινη Χρήση στο πρατήριο της εταιρείας DEKAZ ΑΕhttps://www.pharmaradar360.com/article/regulatory-round-up-20-july-2026-2361df46dde1adc9Pharma Surgeen2026-07-20T07:49:14.000ZRegulatory round-up: 20 July 2026https://www.pharmaradar360.com/article/202412-aloha-nails-cosmetics-repair-gel-milky-lilac-tpo-2fc9b872145d525bPharma Surgeen2026-07-20T07:47:54.000ZΑνάκληση της παρτίδας 202412 του Καλλυντικού προϊόντος ALOHA Nails & Cosmetics REPAIR GEL MILKY LILAC, λόγω παρουσίας TPOhttps://www.pharmaradar360.com/article/world-usp-grade-magnesium-hydroxide-market-analysis-forecast-size-trends-and-ins-44765223f03285f7Pharma Surgeen2026-07-20T07:46:12.000ZWorld Usp Grade Magnesium Hydroxide - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/272955-ivd-general-kits-sta-c-k-prest-bb425a5b49d75aafPharma Surgeen2026-07-20T07:39:33.000ZΑνάκληση της παρτίδας 272955 του Ιατροτεχνολογικού προϊόντος κατηγορίας IVD General, Kits STA- C.K. Prest.https://www.pharmaradar360.com/article/maharashtra-fda-plans-us-style-digital-food-safety-system-blockchain-tracking-as-fa613b86e31c7cc1Pharma Surgeen2026-07-20T07:20:07.000ZMaharashtra FDA Plans US-Style Digital Food Safety System, Blockchain Tracking as Complaints Surgehttps://www.pharmaradar360.com/article/92890-cotton-absorbent-gauze-ref-6-1003-2-ref-6-1006-2-0169395d712d78acPharma Surgeen2026-07-20T07:19:11.000ZΑπόφαση απαγόρευσης διακίνησης και διάθεσης – 92890 Cotton absorbent gauze (REF: 6-1003Ν2 & REF: 6-1006Ν2)https://www.pharmaradar360.com/article/koreabio-seeks-closer-biotech-ties-with-taiwan-15e7326c3b8774a5Pharma Surgeen2026-07-20T07:18:34.000ZKoreaBIO seeks closer biotech ties with Taiwanhttps://www.pharmaradar360.com/article/dimerix-secures-funding-to-advance-dmx-200-phase-3-trial-1a909bb32060c292Pharma Surgeen2026-07-20T07:17:18.000ZDimerix Secures Funding to Advance DMX-200 Phase 3 Trialhttps://www.pharmaradar360.com/article/la-aemps-informa-de-la-entrada-en-aplicacion-del-reglamento-de-ejecucion-ue-2024-c41f098acdc22273Pharma Surgeen2026-07-20T07:16:46.000ZLa AEMPS informa de la entrada en aplicación del Reglamento de Ejecución (UE) 2024/1973 sobre el uso de determinados antimicrobianos en animaleshttps://www.pharmaradar360.com/article/trellis-raises-9m-to-advance-calpurbatug-phase-2-trial-a17a3d5a32117acdPharma Surgeen2026-07-20T07:10:09.000ZTrellis Raises $9M to Advance Calpurbatug Phase 2 Trialhttps://www.pharmaradar360.com/article/coregen-wins-fda-ind-clearance-for-crg-150-c392a1bf28f33ccaPharma Surgeen2026-07-20T07:08:26.000ZCoRegen Wins FDA IND Clearance for CRG-150https://www.pharmaradar360.com/article/what-could-drive-private-capital-participation-in-india-s-biotech-sector-97a8ec88b7ff9f32Pharma Surgeen2026-07-20T07:08:22.000ZWhat could drive private capital participation in India's biotech sector?https://www.pharmaradar360.com/article/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose-8457a82aa7f80a99Pharma Surgeen2026-07-20T07:00:48.000ZEuropean Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year oldshttps://www.pharmaradar360.com/article/when-the-phase-3-dies-after-the-acquisition-the-site-level-fallout-no-one-plans-e2af19f34c1b5bbcPharma Surgeen2026-07-20T07:00:18.000ZWhen the Phase 3 Dies After the Acquisition: The Site-Level Fallout No One Plans Forhttps://www.pharmaradar360.com/article/biovica-receives-first-work-order-under-expanded-master-services-agreement-with-02cfbb4859d1d7a5Pharma Surgeen2026-07-20T07:00:00.000ZBiovica receives first work order under expanded Master Services Agreement with leading global pharmaceutical customerhttps://www.pharmaradar360.com/article/fda-s-ai-complaint-portal-gets-267-complaints-in-pune-division-in-4-days-e6789a91627f8a57Pharma Surgeen2026-07-20T06:59:49.000ZFDA’s AI Complaint Portal Gets 267 Complaints in Pune Division in 4 Dayshttps://www.pharmaradar360.com/article/stepping-up-in-innsbruck-3616a1ea7e13f465Pharma Surgeen2026-07-20T06:54:22.000ZStepping up in Innsbruckhttps://www.pharmaradar360.com/article/cytosurge-elects-veteran-biotech-executive-investor-and-company-builder-luba-gre-eef61bc565bef83ePharma Surgeen2026-07-20T06:45:26.000ZCytosurge elects veteran biotech executive, investor, and company builder Luba Greenwood, J.D., to its Board of Directorshttps://www.pharmaradar360.com/article/fda-raids-two-pmc-hospitals-over-unsafe-drug-dispensing-suspends-10-licences-of-fef7bf0b33eb8269Pharma Surgeen2026-07-20T06:15:17.000ZFDA raids two PMC hospitals over unsafe drug dispensing; suspends 10 licences of eateries, bakeries and dairieshttps://www.pharmaradar360.com/article/big-pharma-s-next-billion-dollar-bet-is-magic-mushrooms-mdma-and-lsd-could-psych-79dd7b298a45a141Pharma Surgeen2026-07-20T06:09:49.000ZBig Pharma's Next Billion-Dollar Bet Is Magic Mushrooms, MDMA And LSD. Could Psychedelic Drugs Change Mental Healthcare Forever?https://www.pharmaradar360.com/article/japanese-drugmaker-takeda-s-qdenga-becomes-first-dengue-vaccine-approved-in-indi-ac24f784c64ba846Pharma Surgeen2026-07-20T06:01:00.000ZJapanese drugmaker Takeda's QDENGA becomes first dengue vaccine approved in Indiahttps://www.pharmaradar360.com/article/takeda-pharmaceutical-s-qdenga-tak-003-becomes-first-dengue-vaccine-to-be-approv-fa4b1e941a201333Pharma Surgeen2026-07-20T05:45:00.000ZTakeda Pharmaceutical's Qdenga (Tak-003) Becomes First Dengue Vaccine To Be Approved In India- Statementhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-tian-an-pharmaceutical-co-ltd-otc-tnph-9334f966b46da200Pharma Surgeen2026-07-20T05:32:26.000ZEnterprise value to EBIT forward of Tian'an Pharmaceutical Co., Ltd. – OTC:TNPHhttps://www.pharmaradar360.com/article/hlb-therapeutics-completes-global-phase-3-patient-enrollment-for-rgn-259-3bb025d0a14ed96aPharma Surgeen2026-07-20T05:29:42.000ZHLB Therapeutics Completes Global Phase 3 Patient Enrollment for RGN-259https://www.pharmaradar360.com/article/hlb-fails-in-third-fda-bid-can-it-rebuild-shattered-market-trust-215dfb485d8834d1Pharma Surgeen2026-07-20T05:23:39.000ZHLB Fails in Third FDA Bid—Can It Rebuild Shattered Market Trust?https://www.pharmaradar360.com/article/atai-stock-slips-after-blockbuster-week-cathie-wood-calls-3-8b-lilly-deal-well-d-b2a2208534949d8bPharma Surgeen2026-07-20T05:18:00.000ZATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholdershttps://www.pharmaradar360.com/article/fostering-new-opportunities-in-the-greater-bay-area-and-asia-s-pharmaceutical-in-f4f3d36ffb101e82Pharma Surgeen2026-07-20T04:52:00.000ZFostering new opportunities in the Greater Bay Area and Asia's Pharmaceutical Industryhttps://www.pharmaradar360.com/article/vietnam-pharma-stocks-gain-attention-as-drug-market-nears-10-billion-a6c0dcb8cc18836fPharma Surgeen2026-07-20T04:29:02.000ZVietnam pharma stocks gain attention as drug market nears $10 billionhttps://www.pharmaradar360.com/article/hong-kong-stocks-in-focus-innovation-driven-pharmaceutical-stocks-rebound-across-1ce48bbe2e7c29e3Pharma Surgeen2026-07-20T04:24:09.000ZHong Kong Stocks in Focus | Innovation‑driven pharmaceutical stocks rebound across the board; 38 innovative drugs received approval for market launch in the first half of the year, with domestically developed products accounting for over 80% of the total.https://www.pharmaradar360.com/article/suven-life-plans-neuroscience-breakthrough-by-2026-27-and-singapore-expansion-3c82c76fd9efd7edPharma Surgeen2026-07-20T04:17:31.000ZSuven Life Plans Neuroscience Breakthrough by 2026-27 and Singapore Expansionhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-aurisco-pharmaceutical-co-ltd-class-a-sse-605116-f67668eac3e5f412Pharma Surgeen2026-07-20T04:15:32.000ZPrice to earnings forward of Aurisco Pharmaceutical Co. Ltd. Class A – SSE:605116https://www.pharmaradar360.com/article/a-pancreatic-cancer-vaccine-shows-promise-in-a-phase-1-clinical-trial-400f6507bfa41d71Pharma Surgeen2026-07-20T04:05:24.000ZA Pancreatic Cancer Vaccine Shows Promise in a Phase 1 Clinical Trialhttps://www.pharmaradar360.com/article/fda-drug-approval-decisions-expected-in-august-2026-6a28147a95c46cb8Pharma Surgeen2026-07-20T04:00:00.000ZFDA Drug Approval Decisions Expected in August 2026https://www.pharmaradar360.com/article/cefiderocol-under-review-for-pediatric-habp-vabp-and-cuti-98434b524b11944bPharma Surgeen2026-07-20T04:00:00.000ZCefiderocol Under Review for Pediatric HABP/VABP and cUTIhttps://www.pharmaradar360.com/article/early-alert-intravascular-administration-set-issue-from-baxter-16cdada857faf0c2Pharma Surgeen2026-07-20T04:00:00.000ZEarly Alert: Intravascular Administration Set Issue from Baxterhttps://www.pharmaradar360.com/article/maha-fda-launches-country-s-first-ai-powered-grievance-portal-to-strengthen-drug-0d57e97bae531cdbPharma Surgeen2026-07-20T03:54:34.000ZMaha FDA launches country's first AI-powered grievance portal to strengthen drug safetyhttps://www.pharmaradar360.com/article/fda-clears-taylor-farms-lettuce-of-cyclospora-contamination-00395b2f818c5b06Pharma Surgeen2026-07-20T03:14:52.000ZFDA Clears Taylor Farms Lettuce of Cyclospora Contaminationhttps://www.pharmaradar360.com/article/is-collegium-pharmaceutical-coll-still-undervalued-as-its-growth-narrative-holds-ed5be6e290a36264Pharma Surgeen2026-07-20T03:14:00.000ZIs Collegium Pharmaceutical (COLL) Still Undervalued As Its Growth Narrative Holds Up?https://www.pharmaradar360.com/article/stay-bullish-despite-the-rough-week-aerospace-finance-biotech-and-ai-ndx-d83081917c32cccePharma Surgeen2026-07-20T02:51:51.000ZStay Bullish Despite The Rough Week: Aerospace, Finance, Biotech, And AI (NDX)https://www.pharmaradar360.com/article/inflammasome-therapeutics-reports-positive-six-month-phase-2-results-for-k8-in-g-31cb61a1131de749Pharma Surgeen2026-07-20T02:46:59.000ZInflammasome Therapeutics Reports Positive Six-Month Phase 2 Results for K8 in Geographic Atrophyhttps://www.pharmaradar360.com/article/world-tablet-capsule-counting-machine-market-analysis-forecast-size-trends-and-i-7d8d204a143b522aPharma Surgeen2026-07-20T02:41:13.000ZWorld Tablet Capsule Counting Machine - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/samsung-biologics-to-launch-1-8-billion-all-cash-bid-for-polypeptide-7baf5c76aeb1e643Pharma Surgeen2026-07-20T01:53:58.000ZSamsung Biologics to launch $1.8 billion all-cash bid for PolyPeptidehttps://www.pharmaradar360.com/article/cyclospora-outbreak-update-fda-clears-taylor-farms-lettuce-bd9d6d6d2b39ec11Pharma Surgeen2026-07-20T01:30:16.000ZCyclospora Outbreak Update: FDA Clears Taylor Farms Lettucehttps://www.pharmaradar360.com/article/korean-pharmaceutical-and-bio-association-launches-gmp-regulation-consultation-h-185445544db2baa7Pharma Surgeen2026-07-20T01:16:00.000ZKorean Pharmaceutical and Bio Association Launches GMP Regulation Consultation Hotlinehttps://www.pharmaradar360.com/article/fda-says-cyclospora-test-on-lettuce-from-taylor-farms-was-a-false-positive-outbr-e80e3caad645c904Pharma Surgeen2026-07-20T00:52:16.000ZFDA says Cyclospora test on lettuce from Taylor Farms was a false positive; outbreak investigation ongoinghttps://www.pharmaradar360.com/article/fda-clears-taylor-farms-in-cyclospora-investigation-35143150d9010bfaPharma Surgeen2026-07-20T00:47:34.000ZFDA Clears Taylor Farms in Cyclospora Investigationhttps://www.pharmaradar360.com/article/osteonic-receives-approval-for-suturepasser-sports-medicine-surgical-tool-accele-0b8fbdc5b6ef664bPharma Surgeen2026-07-20T00:46:17.000ZOsteonic Receives Approval for 'Suturepasser' Sports Medicine Surgical Tool... Accelerates Supply Through Zimmer Biomethttps://www.pharmaradar360.com/article/suven-life-raises-858-cr-for-cns-drug-trials-f34660c423c006fcPharma Surgeen2026-07-20T00:39:53.000ZSuven Life Raises ₹858 Cr for CNS Drug Trialshttps://www.pharmaradar360.com/article/building-a-workforce-engine-for-biomanufacturing-4c6d9e6d8c5d2d93Pharma Surgeen2026-07-20T00:05:33.000ZBuilding a workforce engine for biomanufacturinghttps://www.pharmaradar360.com/article/why-early-de-risking-is-redefining-the-path-to-ind-71ad90a82baa0b7cPharma Surgeen2026-07-20T00:05:33.000ZWhy early de-risking is redefining the path to INDhttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-5085cd4b2e10be8bPharma Surgeen2026-07-20T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-ea4dee9e111b6055Pharma Surgeen2026-07-20T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-73eaec1a2cbd3447Pharma Surgeen2026-07-20T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-1d9a630ce2282e1bPharma Surgeen2026-07-20T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-1f59a12563237366Pharma Surgeen2026-07-20T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-15187d1c341b2c36Pharma Surgeen2026-07-20T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-7b694a87ce4d7353Pharma Surgeen2026-07-20T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-8500f81d6969481bPharma Surgeen2026-07-20T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-40dd926ed1ee3127Pharma Surgeen2026-07-20T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-6b317818e1f5533bPharma Surgeen2026-07-20T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-f69f6cdae0257209Pharma Surgeen2026-07-20T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-6ef7939200ecd808Pharma Surgeen2026-07-20T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-fafa4be92a12a69aPharma Surgeen2026-07-20T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-3a7a96a8b08ce710Pharma Surgeen2026-07-20T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-9d5e7b42638e9db6Pharma Surgeen2026-07-20T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/office-of-the-secretary-amended-notice-of-meeting-8912e2d9dccaf71fPharma Surgeen2026-07-20T00:00:00.000ZOffice of the Secretary; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/privacy-act-of-1974-system-of-records-3b6ec579669d6b19Pharma Surgeen2026-07-20T00:00:00.000ZPrivacy Act of 1974; System of Recordshttps://www.pharmaradar360.com/article/medicare-program-inflation-reduction-act-of-2022-ira-medicare-drug-price-negotia-c4602e089ac69771Pharma Surgeen2026-07-20T00:00:00.000ZMedicare Program; Inflation Reduction Act of 2022 (IRA) Medicare Drug Price Negotiation Program Draft Guidance; Comment Requesthttps://www.pharmaradar360.com/article/food-standards-of-identity-modernization-pasteurized-orange-juice-880832ff9b7e6f11Pharma Surgeen2026-07-20T00:00:00.000ZFood Standards of Identity Modernization; Pasteurized Orange Juicehttps://www.pharmaradar360.com/article/agency-information-collection-request-30-day-public-comment-request-3161abfadc707cedPharma Surgeen2026-07-20T00:00:00.000ZAgency Information Collection Request; 30-Day Public Comment Requesthttps://www.pharmaradar360.com/article/evaluation-of-fructose-zinc-citric-acid-and-sperm-quality-in-infertile-male-subj-cf4fb4f0d20f9e9bPharma Surgeen2026-07-20T00:00:00.000ZEvaluation of Fructose, Zinc, Citric Acid, and Sperm Quality in Infertile Male Subjects Attending Fertility Clinic in Lagos Metropolishttps://www.pharmaradar360.com/article/gender-based-experiences-of-people-living-with-hiv-in-owerri-north-local-governm-47188f034f184747Pharma Surgeen2026-07-20T00:00:00.000ZGender-based Experiences of People Living with HIV in Owerri North Local Government Area of Imo State, Nigeriahttps://www.pharmaradar360.com/article/normative-data-and-repeatability-of-a-4-khz-pure-tone-psychoacoustic-tuning-curv-f925428c472b1fa6Pharma Surgeen2026-07-20T00:00:00.000ZNormative Data and Repeatability of a 4-kHz Pure-Tone Psychoacoustic Tuning Curve Using a Single Clinical Audiometerhttps://www.pharmaradar360.com/article/nanobots-in-lung-cancer-therapy-an-overview-36da52e84dd34725Pharma Surgeen2026-07-20T00:00:00.000ZNanobots in Lung Cancer Therapy: An Overviewhttps://www.pharmaradar360.com/article/antibody-drug-conjugate-combination-therapy-targeting-lgr5-and-met-with-differen-2d9b176848b242f3Pharma Surgeen2026-07-20T00:00:00.000ZAntibody-drug conjugate combination therapy targeting LGR5 and MET with different payloads enhances efficacy in preclinical colorectal cancer modelshttps://www.pharmaradar360.com/article/ancestry-calibrated-polygenic-risk-scores-predict-ptsd-trajectories-in-recent-tr-034f308a09945684Pharma Surgeen2026-07-20T00:00:00.000ZAncestry-Calibrated Polygenic Risk Scores Predict PTSD Trajectories in Recent Trauma Survivors and Interact with Neighborhood Resourceshttps://www.pharmaradar360.com/article/a-closed-loop-age-friendly-medical-platform-from-ai-consultation-to-post-diagnos-c5ef98cdb2096ac1Pharma Surgeen2026-07-20T00:00:00.000ZA CLOSED-LOOP AGE-FRIENDLY MEDICAL PLATFORM: FROM AI CONSULTATION TO POST-DIAGNOSIS CAREhttps://www.pharmaradar360.com/article/interactions-between-hyperglycaemia-drug-metabolism-and-toxicity-profiles-a-syst-fd7b595bf674bef1Pharma Surgeen2026-07-20T00:00:00.000ZInteractions Between Hyperglycaemia, Drug Metabolism, and Toxicity Profiles: A Systems Biology Reviewhttps://www.pharmaradar360.com/article/the-therapeutic-evolution-of-tauroursodeoxycholic-acid-integrating-traditional-w-d1bbc77d669dccd5Pharma Surgeen2026-07-20T00:00:00.000ZThe Therapeutic Evolution of Tauroursodeoxycholic Acid: Integrating Traditional Wisdom with Modern Clinical Applicationshttps://www.pharmaradar360.com/article/meta-analysis-of-the-arterial-variations-of-the-suprarenal-arteries-and-their-cl-6daf84f241efedb6Pharma Surgeen2026-07-20T00:00:00.000ZMeta-Analysis of the Arterial Variations of the Suprarenal Arteries and Their Clinical Significancehttps://www.pharmaradar360.com/article/prevalence-and-clinical-characteristics-of-acute-gastroenteritis-caused-by-rotav-f304f7d2fb2d4c7cPharma Surgeen2026-07-20T00:00:00.000ZPrevalence and Clinical Characteristics of Acute Gastroenteritis Caused by Rotavirus and Adenovirus Among Children Aged ≤ 5 years in a Tertiary Care Hospital in North Indiahttps://www.pharmaradar360.com/article/delineating-the-intradural-space-a-comparative-series-of-spinal-cord-lesions-4d0465044f4b72fcPharma Surgeen2026-07-20T00:00:00.000ZDelineating the Intradural Space: A Comparative Series of Spinal Cord Lesionshttps://www.pharmaradar360.com/article/nurses-experiences-implementing-clinical-practice-guidelines-for-detecting-and-m-713e6360e0c32c4dPharma Surgeen2026-07-20T00:00:00.000ZNurses’ experiences implementing clinical practice guidelines for detecting and managing chronic kidney disease in Eswatini’s primary healthcare facilities: A qualitative studyhttps://www.pharmaradar360.com/article/phenotypic-detection-and-associated-factors-of-ampc-beta-lactamase-among-clinica-50fa90f3277a0cd8Pharma Surgeen2026-07-20T00:00:00.000ZPhenotypic detection and associated factors of AmpC beta-lactamase among clinical isolates of &lt;i&gt;Escherichia coli&lt;/i&gt;, &lt;i&gt;Klebsiella species&lt;/i&gt;, and &lt;i&gt;Proteus species&lt;/i&gt; at the National Hospital of Sri Lankahttps://www.pharmaradar360.com/article/common-single-nucleotide-polymorphisms-in-clinical-cardiology-and-dietary-interv-ae256b1aa1b82672Pharma Surgeen2026-07-20T00:00:00.000ZCommon Single Nucleotide Polymorphisms in Clinical Cardiology and Dietary Intervention: A Narrative Reviewhttps://www.pharmaradar360.com/article/sufentanil-in-intensive-care-a-narrative-review-327270e77d9a5c70Pharma Surgeen2026-07-20T00:00:00.000ZSufentanil in Intensive Care: A Narrative Reviewhttps://www.pharmaradar360.com/article/impact-of-preoperative-teriparatide-use-on-proximal-junctional-kyphosis-preventi-dc034886d7db6d6aPharma Surgeen2026-07-20T00:00:00.000ZImpact of Preoperative Teriparatide Use on Proximal Junctional Kyphosis Prevention in Osteopenic/Osteoporotic Patients Undergoing Adult Spinal Deformity Surgery: A Propensity Score-Matched Studyhttps://www.pharmaradar360.com/article/admission-endothelial-activation-and-stress-index-and-echocardiographic-rv-pa-co-2fbeb3b6c5eda27aPharma Surgeen2026-07-20T00:00:00.000ZAdmission Endothelial Activation and Stress Index and Echocardiographic RV-PA Coupling for Early Risk Stratification in Intermediate-Risk Acute Pulmonary Embolismhttps://www.pharmaradar360.com/article/safe-implementation-of-robotic-colorectal-surgery-balancing-surgical-training-an-a4c2a2190bddac1dPharma Surgeen2026-07-20T00:00:00.000ZSafe Implementation of Robotic Colorectal Surgery: Balancing Surgical Training and Patient Safety with the Dual-Console Systemhttps://www.pharmaradar360.com/article/patient-reported-health-status-and-clinical-outcomes-after-cto-pci-versus-optima-c82cba1acac8a1ccPharma Surgeen2026-07-20T00:00:00.000ZPatient-Reported Health Status and Clinical Outcomes After CTO-PCI Versus Optimal Medical Therapy: A 12-Month Retrospective Observational Cohort Analysishttps://www.pharmaradar360.com/article/an-equity-embedded-protocol-agnostic-pre-trial-navigation-model-for-canadian-blo-a702face4fad5433Pharma Surgeen2026-07-20T00:00:00.000ZAn Equity-Embedded, Protocol-Agnostic Pre-Trial Navigation Model for Canadian Blood Cancer Trials: Findings from the Myeloma Canada Phase 0 Workshophttps://www.pharmaradar360.com/article/sars-cov-2-wastewater-surveillance-in-a-central-chinese-metropolis-variant-respo-f66899a9396ac66dPharma Surgeen2026-07-20T00:00:00.000ZSARS-CoV-2 wastewater surveillance in a central Chinese metropolis: variant responses and correlation with clinical caseshttps://www.pharmaradar360.com/article/comparison-of-intraoperative-hemodynamic-parameters-between-propofol-and-remimaz-125f116cc3423af1Pharma Surgeen2026-07-20T00:00:00.000ZComparison of intraoperative hemodynamic parameters between propofol- and remimazolam-based total intravenous anesthesia in patients undergoing robotic gynecologic surgery: a randomized controlled trial protocolhttps://www.pharmaradar360.com/article/radiomics-and-clinical-data-predict-pseudoprogression-after-radiotherapy-in-high-3104fb64e4d15ae0Pharma Surgeen2026-07-20T00:00:00.000ZRadiomics and clinical data predict pseudoprogression after radiotherapy in high-grade gliomahttps://www.pharmaradar360.com/article/clinical-imaging-fusion-model-for-risk-assessment-of-clinically-significant-pros-f45ed9722b9521dcPharma Surgeen2026-07-20T00:00:00.000ZClinical-imaging fusion model for risk assessment of clinically significant prostate cancerhttps://www.pharmaradar360.com/article/low-energy-availability-the-gut-microbiome-and-bone-health-in-athletes-a-mechani-3ef1f487c33a3f9ePharma Surgeen2026-07-20T00:00:00.000ZLow energy availability, the gut microbiome, and bone health in athletes: a mechanistic narrative review based on athlete evidence and clinical analogueshttps://www.pharmaradar360.com/article/efficacy-of-intradermal-acupuncture-for-ocular-surface-diseases-secondary-to-ref-5aa9dd4dd10a6942Pharma Surgeen2026-07-20T00:00:00.000ZEfficacy of intradermal acupuncture for ocular surface diseases secondary to refractory peripheral facial palsy: a randomized controlled trial study protocolhttps://www.pharmaradar360.com/article/changing-trends-in-antibiotic-susceptibility-pattern-among-clinical-isolates-of-ac74a164769f98b0Pharma Surgeen2026-07-20T00:00:00.000ZChanging Trends in Antibiotic Susceptibility Pattern Among Clinical Isolates of &lt;i&gt;Pseudomonas&lt;/i&gt; Species in a Tertiary Care Hospital in Nepalhttps://www.pharmaradar360.com/article/advancing-polypharmacology-based-drug-discovery-using-deep-generative-models-3ec4c14495c7385ePharma Surgeen2026-07-20T00:00:00.000ZAdvancing polypharmacology-based drug discovery using deep generative modelshttps://www.pharmaradar360.com/article/clinical-reflection-and-reasoning-competencies-among-nursing-students-in-health-75734b6b7ceefb2bPharma Surgeen2026-07-20T00:00:00.000ZClinical Reflection and Reasoning Competencies among Nursing Students in Health Science Universities: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/transcriptome-wide-identification-of-hub-genes-and-therapeutic-targets-in-type-2-9c0b13d71b628c6bPharma Surgeen2026-07-20T00:00:00.000ZTranscriptome-Wide Identification of Hub Genes and Therapeutic Targets in Type 2 Diabetes Mellitus Through Integrated Bioinformatics and Molecular Docking-Based Drug Repurposinghttps://www.pharmaradar360.com/article/clinical-characteristics-and-outcomes-of-adult-patients-presenting-to-the-emerge-1c3074fb16e39293Pharma Surgeen2026-07-20T00:00:00.000ZClinical Characteristics and Outcomes of Adult Patients Presenting to the Emergency Department After Hanging: An Eight-Year Retrospective Studyhttps://www.pharmaradar360.com/article/effects-of-practice-testing-with-corrective-feedback-on-long-term-bpsd-knowledge-f0351eefe220bde8Pharma Surgeen2026-07-20T00:00:00.000ZEffects of Practice Testing with Corrective Feedback on Long-Term BPSD Knowledge in Dementia Caregivers: Randomized Controlled Trialhttps://www.pharmaradar360.com/article/digital-planning-and-navigation-in-sinus-lifting-surgery-description-of-a-clinic-d519be35d6aec2daPharma Surgeen2026-07-20T00:00:00.000ZDigital planning and navigation in sinus lifting surgery. (Description of a clinical case)https://www.pharmaradar360.com/article/epidemiological-and-clinical-features-of-tumors-of-the-parotid-salivary-glands-i-52a89a81624afa32Pharma Surgeen2026-07-20T00:00:00.000ZEpidemiological and clinical features of tumors of the parotid salivary glands in the Republic of Khakassiahttps://www.pharmaradar360.com/article/social-inequities-in-high-risk-neonatal-care-delivery-clinical-report-445e5bfc2f37a182Pharma Surgeen2026-07-20T00:00:00.000ZSocial Inequities in High-Risk Neonatal Care Delivery: Clinical Reporthttps://www.pharmaradar360.com/article/clinical-legal-education-in-international-environmental-disputes-lessons-from-th-d845e54ad559f760Pharma Surgeen2026-07-20T00:00:00.000ZClinical Legal Education in International Environmental Disputes: Lessons from the Montara Oil Spill Disputehttps://www.pharmaradar360.com/article/comparative-efficacy-of-promising-targets-in-the-treatment-of-metabolic-dysfunct-caf7000126f1a8b8Pharma Surgeen2026-07-20T00:00:00.000ZComparative Efficacy of Promising Targets in the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Network Meta-analysishttps://www.pharmaradar360.com/article/propensity-score-matched-external-controls-in-rare-disease-trials-a-promising-to-304a7558599a6773Pharma Surgeen2026-07-20T00:00:00.000ZPropensity Score–Matched External Controls in Rare Disease Trials: A Promising Tool Requiring Rigorous Validationhttps://www.pharmaradar360.com/article/neoadjuvant-sacituzumab-govitecan-in-patients-with-muscle-invasive-bladder-cance-b9c1d0176e76f110Pharma Surgeen2026-07-20T00:00:00.000ZNeoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trialhttps://www.pharmaradar360.com/article/integrative-molecular-analysis-reveals-determinants-of-clinical-outcomes-in-i-tp-9a666ee8e92ed002Pharma Surgeen2026-07-20T00:00:00.000ZIntegrative Molecular Analysis Reveals Determinants of Clinical Outcomes in <i>TP53</i> -Mutated Diffuse Large B-Cell Lymphomahttps://www.pharmaradar360.com/article/clinical-memory-functionalisation-and-fragmentation-of-care-in-uk-psychiatry-3d2ffea0d0590ad0Pharma Surgeen2026-07-20T00:00:00.000ZClinical memory, functionalisation and fragmentation of care in UK psychiatryhttps://www.pharmaradar360.com/article/diagnostic-and-clinical-impact-of-point-of-care-ultrasonography-in-internal-medi-e7b6f33867f50136Pharma Surgeen2026-07-20T00:00:00.000ZDiagnostic and clinical impact of point-of-care ultrasonography in internal medicine wards: a systematic review of its role in imaging-guided decision-makinghttps://www.pharmaradar360.com/article/lumefantrine-quantification-on-pre-treated-filter-paper-dried-blood-spots-for-cl-bf894c3a6b580cb1Pharma Surgeen2026-07-20T00:00:00.000ZLumefantrine quantification on pre-treated filter paper dried blood spots for clinical field trialshttps://www.pharmaradar360.com/article/efficacy-and-safety-of-albendazole-versus-praziquantel-in-the-treatment-of-clono-e43d33f6f124fcf5Pharma Surgeen2026-07-20T00:00:00.000ZEfficacy and safety of albendazole versus praziquantel in the treatment of Clonorchis sinensis infection: an infection intensity-stratified, open-label, phase 2, randomized controlled trialhttps://www.pharmaradar360.com/article/effectiveness-of-s-prg-based-varnish-and-bioactive-glass-based-air-polishing-in-c92066bd94951723Pharma Surgeen2026-07-20T00:00:00.000ZEffectiveness of S-PRG–based varnish and bioactive glass–based air polishing in the management of dentin hypersensitivity and their effects on tooth color: a 12-month randomized clinical trialhttps://www.pharmaradar360.com/article/effects-of-resistance-band-shoulder-exercise-on-pain-range-of-motion-and-functio-492d780dcc9eba7bPharma Surgeen2026-07-20T00:00:00.000ZEffects of resistance-band shoulder exercise on pain, range of motion, and functional disability in diabetic adults with adhesive capsulitis: a pilot randomized controlled trialhttps://www.pharmaradar360.com/article/a-randomized-controlled-trial-of-brachial-plexus-block-manipulation-versus-stero-130bce84d291b7e3Pharma Surgeen2026-07-20T00:00:00.000ZA randomized controlled trial of brachial plexus block manipulation versus steroid injection in conscious patients for moderate to severe shoulder stiffnesshttps://www.pharmaradar360.com/article/long-term-clinical-outcomes-and-complications-after-open-reduction-and-internal-6d4757ff05dbb25fPharma Surgeen2026-07-20T00:00:00.000ZLong-term clinical outcomes and complications after Open Reduction and Internal Fixation (ORIF) with locking plate for proximal humerus fractures: a systematic review and meta-analysishttps://www.pharmaradar360.com/article/exploratory-clinical-ct-machine-learning-characterization-of-ck7-expression-in-c-69ed892cd38c51d8Pharma Surgeen2026-07-20T00:00:00.000ZExploratory clinical-CT machine learning characterization of CK7 expression in clear cell renal cell carcinomahttps://www.pharmaradar360.com/article/a-novel-homozygous-frameshift-mutation-in-cfap65-is-associated-with-multiple-mor-64fbf1f475d767cdPharma Surgeen2026-07-20T00:00:00.000ZA novel homozygous frameshift mutation in CFAP65 is associated with multiple morphological abnormalities of sperm flagella in a consanguineous Pakistani familyhttps://www.pharmaradar360.com/article/integrated-proteomics-and-machine-learning-for-identifying-candidate-serum-bioma-f56f367ae6b92f78Pharma Surgeen2026-07-20T00:00:00.000ZIntegrated proteomics and machine learning for identifying candidate serum biomarkers in acute myocardial infarction-complicated cardiogenic shock: a prospective exploratory studyhttps://www.pharmaradar360.com/article/beyond-amplification-precision-approaches-to-targeting-her2-7c5d012331d4c8e0Pharma Surgeen2026-07-20T00:00:00.000ZBeyond Amplification: Precision Approaches to Targeting HER2https://www.pharmaradar360.com/article/draft-genome-sequence-of-i-enterobacter-roggenkampii-i-strain-mbbl-mp5-isolated-1c71675268a519e2Pharma Surgeen2026-07-20T00:00:00.000ZDraft genome sequence of <i>Enterobacter roggenkampii</i> strain MBBL_MP5 isolated from dairy cow with clinical mastitishttps://www.pharmaradar360.com/article/reconsidering-throat-swab-culture-in-melioidosis-diagnostic-stewardship-with-cli-b499e54930aca45bPharma Surgeen2026-07-20T00:00:00.000ZReconsidering throat swab culture in melioidosis: diagnostic stewardship with clinical nuancehttps://www.pharmaradar360.com/article/masking-recurrent-contaminants-in-reference-sequences-improves-specificity-of-cl-023b0ad8af6b5bb3Pharma Surgeen2026-07-20T00:00:00.000ZMasking recurrent contaminants in reference sequences improves specificity of clinical metagenomic sequencinghttps://www.pharmaradar360.com/article/sperm-mitochondrial-dna-copy-number-and-nuclear-dna-methylation-across-clinical-d18f99a1b0b0afb6Pharma Surgeen2026-07-20T00:00:00.000ZSperm Mitochondrial DNA Copy Number and Nuclear DNA Methylation Across Clinical and Non‐Clinical Preconception Cohortshttps://www.pharmaradar360.com/article/in-favor-d76f6e3433bb22faPharma Surgeen2026-07-20T00:00:00.000ZIn Favorhttps://www.pharmaradar360.com/article/evaluation-of-model-informed-precision-dosing-of-cefepime-in-critically-ill-pati-d11e879eee5d52b1Pharma Surgeen2026-07-20T00:00:00.000ZEvaluation of Model-Informed Precision Dosing of Cefepime in Critically Ill Patients: A French Before–After Studyhttps://www.pharmaradar360.com/article/long-term-efficacy-and-safety-of-rehabilitation-in-patients-with-pulmonary-arter-b57a27038135e0d6Pharma Surgeen2026-07-20T00:00:00.000ZLong-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the FONCE-HTAP randomized controlled trialhttps://www.pharmaradar360.com/article/a-monte-carlo-simulation-tool-to-analyze-breast-cancer-trial-outcomes-applicatio-d1709bb0e502ba8fPharma Surgeen2026-07-20T00:00:00.000ZA Monte Carlo simulation tool to analyze breast cancer trial outcomes: application to FAST-Forward trialhttps://www.pharmaradar360.com/article/efficacy-and-safety-of-a-novel-532-nm-picosecond-nd-yag-laser-for-the-treatment-c18aa9a38b2fe257Pharma Surgeen2026-07-20T00:00:00.000ZEfficacy and safety of a novel 532-nm picosecond Nd:YAG laser for the treatment of freckles in Chinese patients: a randomized, split-face, multicenter, noninferiority trialhttps://www.pharmaradar360.com/article/the-changing-face-of-uk-academic-drug-screening-in-the-past-decade-c4f3cf6842d0fb96Pharma Surgeen2026-07-20T00:00:00.000ZThe changing face of UK academic drug screening in the past decadehttps://www.pharmaradar360.com/article/the-effect-of-youth-caregiver-discrepancies-in-reports-of-internalizing-and-exte-a4ca0abe5efdef9dPharma Surgeen2026-07-20T00:00:00.000ZThe effect of youth–caregiver discrepancies in reports of internalizing and externalizing behavior in forensic clinical decision making about youth involved in the justice system.https://www.pharmaradar360.com/article/comparative-evaluation-of-anti-cancer-activity-of-free-and-nano-encapsulated-gal-b328ec73edd305efPharma Surgeen2026-07-20T00:00:00.000ZComparative evaluation of anti-cancer activity of free and nano-encapsulated gallic acid in PC-3 and HEK-293 cellshttps://www.pharmaradar360.com/article/genomic-insights-and-pathogenic-potential-of-begomovirus-infecting-bitter-gourd-b4d51e30acf35774Pharma Surgeen2026-07-20T00:00:00.000ZGenomic insights and pathogenic potential of begomovirus infecting bitter gourd (Momordica charantia L.) in Tamil nadu, Indiahttps://www.pharmaradar360.com/article/sildenafil-associated-severe-cholestatic-drug-induced-liver-injury-presenting-as-bc95b674f4c8fb91Pharma Surgeen2026-07-20T00:00:00.000ZSildenafil-associated severe cholestatic drug-induced liver injury presenting as persistent jaundice after stone extractionhttps://www.pharmaradar360.com/article/clinical-remission-with-ff-umec-vi-versus-ics-laba-in-uncontrolled-asthma-the-pe-a29ba614d519d472Pharma Surgeen2026-07-20T00:00:00.000ZClinical Remission with FF/UMEC/VI Versus ICS/LABA in Uncontrolled Asthma: The PERFORM Pragmatic Randomized Controlled Trialhttps://www.pharmaradar360.com/article/clinical-usefulness-of-slab-selective-three-dimensional-magnetic-resonance-angio-c0894178ea0b833fPharma Surgeen2026-07-20T00:00:00.000ZClinical usefulness of slab-selective three-dimensional magnetic resonance angiography using radial stack-of-stars acquisition and UTE sampling (STARS UTE-MRA) after treatment of cerebral aneurysms with metallic deviceshttps://www.pharmaradar360.com/article/deciphering-survival-disparities-in-endometrial-cancer-a-focus-on-mismatch-repai-034298080b5f310fPharma Surgeen2026-07-20T00:00:00.000ZDeciphering survival disparities in endometrial cancer: a focus on mismatch repair pathway integrity (systematic review and meta-analysis)https://www.pharmaradar360.com/article/research-evolution-and-clinical-positioning-of-robot-assisted-simple-prostatecto-926a42128cd0704cPharma Surgeen2026-07-20T00:00:00.000ZResearch evolution and clinical positioning of robot-assisted simple prostatectomy for benign prostatic hyperplasia: a bibliometric and visualization analysishttps://www.pharmaradar360.com/article/mapping-the-evolution-of-deep-learning-and-computer-vision-in-robotic-surgery-a-898ea3c81aa196b7Pharma Surgeen2026-07-20T00:00:00.000ZMapping the evolution of deep learning and computer vision in robotic surgery: a bibliometric analysis of surgical video intelligence, instrument perception, and clinical translationhttps://www.pharmaradar360.com/article/dfdba-plus-t-prf-with-and-without-vitamin-d3-gel-in-intrabony-defects-a-randomiz-94b6a4bbaf17b04bPharma Surgeen2026-07-20T00:00:00.000ZDFDBA plus T-PRF with and without vitamin D3 gel in intrabony defects: a randomized controlled trialhttps://www.pharmaradar360.com/article/effects-of-medical-mud-pack-therapy-on-inflammatory-gene-expression-and-clinical-47650b73d2ae0513Pharma Surgeen2026-07-20T00:00:00.000ZEffects of medical mud-pack therapy on inflammatory gene expression and clinical outcomes in patients with knee osteoarthritishttps://www.pharmaradar360.com/article/association-between-pupil-size-and-response-to-atropine-therapy-in-the-atropine-5f7c987ebc2a0ac8Pharma Surgeen2026-07-20T00:00:00.000ZAssociation between pupil size and response to atropine therapy in the Atropine Treatment of Myopia study (ATOM2)https://www.pharmaradar360.com/article/effect-of-vicryl-7-0-suturing-versus-diathermy-closure-on-the-ocular-surface-aft-81bf35af238f9a96Pharma Surgeen2026-07-20T00:00:00.000ZEffect of vicryl 7 − 0 suturing versus diathermy closure on the ocular surface after small-gauge vitrectomy: a prospective randomized studyhttps://www.pharmaradar360.com/article/transanastomotic-tube-following-surgery-for-congenital-duodenal-obstruction-its-4cb7a1da843035d2Pharma Surgeen2026-07-20T00:00:00.000ZTransanastomotic tube following surgery for congenital duodenal obstruction: its effect on nutrition and clinical outcomeshttps://www.pharmaradar360.com/article/acceleration-of-canine-retraction-with-conventional-versus-modified-piezocision-5b851e5df0784193Pharma Surgeen2026-07-20T00:00:00.000ZAcceleration of canine retraction with conventional versus modified piezocision techniqueshttps://www.pharmaradar360.com/article/the-impact-of-prehabilitation-on-clinical-outcomes-in-liver-surgery-a-systematic-689836f456de4a37Pharma Surgeen2026-07-20T00:00:00.000ZThe Impact of Prehabilitation on Clinical Outcomes in Liver Surgery: A Systematic Review and Meta‐Analysishttps://www.pharmaradar360.com/article/optimal-scp-pvc-scp-reactor-temperature-and-viscosity-control-for-automated-manu-bec9e1133491964dPharma Surgeen2026-07-20T00:00:00.000ZOptimal <scp>PVC</scp> reactor temperature and viscosity control for automated manufacturing cells based on machine learning and internet of thingshttps://www.pharmaradar360.com/article/serum-methylmalonic-acid-levels-and-epilepsy-prevalence-association-analysis-exp-e80865bd5ca369a3Pharma Surgeen2026-07-20T00:00:00.000ZSerum methylmalonic acid levels and epilepsy prevalence: Association analysis, exploratory mediation, and clinical corroborationhttps://www.pharmaradar360.com/article/from-models-to-meaning-the-integrator-pharmacologist-s-role-in-advancing-health-a8b57ac0015eb1f7Pharma Surgeen2026-07-20T00:00:00.000ZFrom Models to Meaning: The Integrator Pharmacologist's Role in Advancing Health Equity Across the Drug Development Continuumhttps://www.pharmaradar360.com/article/nct07715760-efficacy-and-mechanistic-evaluation-of-hewei-anchang-formula-for-ove-7c7a4b9cf8e0c326Pharma Surgeen2026-07-20T00:00:00.000ZNCT07715760: Efficacy and Mechanistic Evaluation of Hewei Anchang Formula for Overlapping Gastrointestinal Symptoms in Patients With Coexisting Functional Dyspepsia and Diarrhea-Predominant Irritable Bowel Syndromehttps://www.pharmaradar360.com/article/nct07715292-the-influence-of-passive-local-muscle-vibration-on-mechanical-power-19c2ba6708726a3ePharma Surgeen2026-07-20T00:00:00.000ZNCT07715292: The Influence of Passive Local Muscle Vibration on Mechanical Power Output and Neuromuscular Activity During Counterbalanced RPE-clamped Cycling: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/nct07715266-safety-and-performance-of-a-new-medical-device-on-post-cataract-surg-f01f0dc43c8c3e9cPharma Surgeen2026-07-20T00:00:00.000ZNCT07715266: SAFETY AND PERFORMANCE OF A NEW MEDICAL DEVICE ON POST CATARACT SURGERY DRY EYE DISEASEhttps://www.pharmaradar360.com/article/nct07715149-a-pharmacokinetic-study-of-d-2570-in-participants-with-hepatic-impai-2025b8c50c01d756Pharma Surgeen2026-07-20T00:00:00.000ZNCT07715149: A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic Functionhttps://www.pharmaradar360.com/article/nct07714395-evaluate-preliminary-anti-tumor-activity-of-elraglusib-in-adult-part-d94a57ece9eed24dPharma Surgeen2026-07-20T00:00:00.000ZNCT07714395: Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumorshttps://www.pharmaradar360.com/article/nct07714382-survival-outcomes-of-residual-disease-in-triple-negative-breast-canc-26a8ae1e0f02d7a5Pharma Surgeen2026-07-20T00:00:00.000ZNCT07714382: Survival Outcomes of Residual Disease in Triple-Negative Breast Cancerhttps://www.pharmaradar360.com/article/nct07714044-rutgers-university-study-of-the-genetics-of-blood-cancers-5941451d6ed2f344Pharma Surgeen2026-07-20T00:00:00.000ZNCT07714044: Rutgers University Study of the Genetics of Blood Cancershttps://www.pharmaradar360.com/article/nct07714018-comparing-two-weight-loss-programs-for-the-prevention-of-kidney-canc-368c5483fccccefcPharma Surgeen2026-07-20T00:00:00.000ZNCT07714018: Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillancehttps://www.pharmaradar360.com/article/nct07713602-study-to-assess-safety-and-clinical-responses-with-coartem-baby-disp-9925566465ef77cdPharma Surgeen2026-07-20T00:00:00.000ZNCT07713602: Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in Paediatric Patients Weighing 2 to <5 kg With Uncomplicated Malariahttps://www.pharmaradar360.com/article/nct07713459-a-phase-ii-study-to-evaluate-the-efficacy-of-uf-kure19-cells-in-pati-e5ddb85b13e5e1a4Pharma Surgeen2026-07-20T00:00:00.000ZNCT07713459: A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomashttps://www.pharmaradar360.com/article/nct07713290-a-phase-1b-study-of-gkl-006-injection-in-patients-with-unresectable-e255ee4ad967bfadPharma Surgeen2026-07-20T00:00:00.000ZNCT07713290: A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinomahttps://www.pharmaradar360.com/article/nct07713251-supporting-adolescent-alcohol-treatment-with-computer-based-path180-d31b8ea12e556229Pharma Surgeen2026-07-20T00:00:00.000ZNCT07713251: Supporting Adolescent Alcohol Treatment With Computer-Based ('Path180') Skills Traininghttps://www.pharmaradar360.com/article/nct07712848-dec3-ven-vs-venetoclax-based-vs-da-regimens-in-newly-diagnosed-aml-2aaf2f1318ad74eaPharma Surgeen2026-07-20T00:00:00.000ZNCT07712848: DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AMLhttps://www.pharmaradar360.com/article/nct07708181-a-study-of-ssgj-613-in-gout-participants-initiating-urate-lowering-t-99961428e6dd33e2Pharma Surgeen2026-07-20T00:00:00.000ZNCT07708181: A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatmenthttps://www.pharmaradar360.com/article/nct07706582-management-of-iron-deficiency-anemia-in-hemodialysis-patients-66d6ef22d493fc03Pharma Surgeen2026-07-20T00:00:00.000ZNCT07706582: Management of Iron Deficiency Anemia in Hemodialysis Patientshttps://www.pharmaradar360.com/article/nct07701655-personalized-approach-to-celiac-disease-diagnosis-0976617d870ef076Pharma Surgeen2026-07-20T00:00:00.000ZNCT07701655: Personalized Approach to Celiac Disease Diagnosishttps://www.pharmaradar360.com/article/nct07701616-digital-mindfulness-based-therapy-for-obsessive-compulsive-disorder-cda2ce9995887653Pharma Surgeen2026-07-20T00:00:00.000ZNCT07701616: Digital Mindfulness-Based Therapy for Obsessive-Compulsive Disorder